TY - JOUR
T1 - Sleep apnea
T2 - Implications for heart failure
AU - Olson, Lyle J.
AU - Somers, Virend K.
N1 - Funding Information:
Dr. Olson is supported by National Institute of Health grants HL-65176, HL-71478 and M01-RR00585 and the Mayo Foundation. Dr. Somers is supported by National Institute of Health grants HL-65176, HL-70302, HL-73211 and M01-RR00585 and the Mayo Foundation. Dr. Olson has been a consultant for the Medtronic Corporation and has an unrestricted research grant from the Medtronic Corporation. Dr. Somers is a consultant for Respironics and Cardiac Concepts, coinvestigator for a study funded with a grant from ResMed Foundation, and has received an honorarium from ResMed.
PY - 2007/6
Y1 - 2007/6
N2 - It is likely sleep apnea is highly prevalent in patients with congestive heart failure (CHF). However, as awareness is low and consensus guidelines do not exist, sleep apnea is not routinely screened for or diagnosed in CHF practice. Untreated sleep apnea may promote fatigue as well as left ventricular dysfunction, disease progression, and increased mortality. Available screening tools lack sensitivity or specificity, and there are insufficient numbers of sleep laboratories to accommodate the potentially large number of patient referrals with CHF for definitive diagnosis. In CHF patients with obstructive sleep apnea and sleepiness, treatment includes continuous positive airway pressure which may improve left ventricular function; optimal treatment for the non-sleepy patient is not established. There is no consensus regarding treatment for central sleep apnea. Studies which evaluate cardiovascular endpoints will be necessary to define management strategies for patients with CHF and either obstructive or central sleep apnea.
AB - It is likely sleep apnea is highly prevalent in patients with congestive heart failure (CHF). However, as awareness is low and consensus guidelines do not exist, sleep apnea is not routinely screened for or diagnosed in CHF practice. Untreated sleep apnea may promote fatigue as well as left ventricular dysfunction, disease progression, and increased mortality. Available screening tools lack sensitivity or specificity, and there are insufficient numbers of sleep laboratories to accommodate the potentially large number of patient referrals with CHF for definitive diagnosis. In CHF patients with obstructive sleep apnea and sleepiness, treatment includes continuous positive airway pressure which may improve left ventricular function; optimal treatment for the non-sleepy patient is not established. There is no consensus regarding treatment for central sleep apnea. Studies which evaluate cardiovascular endpoints will be necessary to define management strategies for patients with CHF and either obstructive or central sleep apnea.
UR - https://www.scopus.com/pages/publications/34250712752
UR - https://www.scopus.com/pages/publications/34250712752#tab=citedBy
U2 - 10.1007/s11897-007-0002-9
DO - 10.1007/s11897-007-0002-9
M3 - Review article
C2 - 17521497
AN - SCOPUS:34250712752
SN - 1546-9530
VL - 4
SP - 63
EP - 69
JO - Current heart failure reports
JF - Current heart failure reports
IS - 2
ER -